Spots Global Cancer Trial Database for A Study of ZG005 Combined With Donafenib in Patients With Advanced Solid Tumor
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of ZG005 Combined With Donafenib in Patients With Advanced Solid Tumor
Official Title: A Multi-center, Open, Dose Exploration and Dose Expansion Phase I/II Study of ZG005 Combined With Donafenib Tosilate Tablets in Patients With Advanced Solid Tumor
Study ID: NCT06239298
Conditions
Study Description
Brief Summary: This is a Multi-center, Open-labe, Phase I/II Study to evaluate the safety and tolerability of ZG005 Combined With Donafenib in Patients With Advanced Solid Tumor.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
The Second Affiliated Hospital of Army Medical University, Chongqing, Chongqing, China
Contact Details
Name: Jason Wu
Affiliation: Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
